money moves

Houston fund makes first local investment in $8M deal

A Houston-based fund has deployed capital into a local nutritional supplement business. Photo via Instagram

A Houston-based investment fund has announced its its latest deal that includes an investment into a local direct-to-consumer supplement company.

GP Capital Partners has invested in Qualitas Health, known as iwi, which produces plant-based omega-3 and protein products that's sold directly to consumers as well as retailers across the United States. Iwi's nutrition supplement is sustainably sourced from the company's cultivation pond systems, which are the size of football fields and located in New Mexico and Texas.

“We are excited about our investment in iwi. They have a proprietary and scalable process to create in-demand products in a sustainable manner," says Gina Luna, principal of the fund, in the news release. "We look forward to working with iwi’s management team as they pursue this transformative opportunity.”

The $8 million deal — $5.5 million in senior secured term debt and a $2.5 million direct equity investment — will help iwi accelerate sales of its existing products and ramp up development, marketing, and growth of new protein-based product, according to the release. Iwi will also enter new international markets.

“The iwi team looks forward to working with GP Capital Partners following their investment in our growing company. We have big plans for accelerating our growth, and are pleased to partner with this team that brings both expertise and relationships to support us in this new stage of the company," says Miguel Calatayud, CEO of iwi, in the release.

Outside of GP, the Houston company's other investors include Grupo Indukern, Gullspång Re:food VC, PeakBridge VC, , Arancia Group, Trucent, SASA, and Minrav. GP launched its $275 million fund last year. It's structured as a Small Business Investment Company and will deploy funding into 20 to 25 companies within the Gulf Coast region.

The supplement company is based in Houston. Photo via Instagram

Trending News

Building Houston

 
 

Houston-based Melax Tech has developed multiple Natural language processing tools that are used by more than 650 health care and life science organizations. Photo via MelaxTech.com

Melax Tech Partners, a leader in natural language technology processing, announced a new partnership with the University of California at Irvine that will help researchers derive insights from the UCI Health Data Science Platform’s electronic health records system and improve patient care.

Melax will implement its signature text annotation tool LANN to pull information from clinical notes, and its CLAMP product to develop natural language processing customizations through the use of AI, according to a statement from the company.

“There has been a strong desire among UCI researchers to have the capability to analyze free-text clinical narrative data using cutting-edge NLP technologies," Kai Zheng, chief research information officer at UCI Health Affairs, says in a statement. "We are delighted to have this opportunity to work with Melax Tech to deploy their AI-driven annotation and analytics tools to help our researchers advance their research agenda by leveraging the vast amount of free-text data that our health system has accumulated in the past two decades.”

Natural language processing, or NLP, allows organizations and healthcare groups to sift through and analyze massive amounts of data at a rapid rate through the use of machine learning and AI. Houston-based Melax Tech, founded in 2017, has developed multiple NLP tools that are used by more than 650 health care and life science organizations, according to its website.

In addition to the recent partnership with UC Irvine, Melax has also recently partnered with Vanderbilt University Medical Center and the University of Western Pennsylvania on similar clinical projects.

Melax has also used its platforms to pull vital information from datasets relating to COVID-19, in both medical and social settings.

In March 2022, it was awarded a Phase 1 NIH Award, valued at $300,000, to develop informatics tools based on COVID-19 datasets with the San Diego Supercomputer Center at UC San Diego. The tool aims to help researchers better understand vast amounts of virus-related data and connect findings with other similar results.

In August, Melax also received another $300,000 grant from the National Institute of Allergy and Infectious Diseases to develop NLP-based algorithms that will "model, extract and synthesize vaccine misinformation from multiple popular social media sources," according to a statement. Melax will also develop a visualization that presents its findings on the misinformation into a compressible format.

"This is a very real topic affecting culture at present," Andre Pontin, CEO at Melax Tech, says in a statement. "And shows that we as a collective business and group of experts continue to be on the cutting-edge of science in the NLP and AI domain."

Trending News